Briobacept

Drug Profile

Briobacept

Alternative Names: BAFF-R protein therapeutic - Biogen Idec/Genentech; BLyS neutralizing molecule; BR3 Fc - Biogen Idec/Genentech

Latest Information Update: 31 May 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec; Genentech
  • Class Antirheumatics; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action B cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Rheumatoid arthritis; Sjogren's syndrome

Most Recent Events

  • 14 Jun 2008 Pharmacokinetics, pharmacodynamics and adverse events data from a trial in rheumatoid arthritis presented at the Annual European Congress of Rheumatology (EULAR-2008)
  • 29 Nov 2006 Data presented at the 70th Annual Scientific Meeting of the American College of Rheumatology(ACR-2006) added to the adverse events, pharmacokinetics, Rheumatic Disease pharmacodynamics and immunogenicity sections
  • 06 Jul 2006 Phase-II clinical trials in Sjogren's syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top